0
     

Report Added
Report already added
Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Drugs In Development, 2022, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, Preclinical and Unknown stages are 12, 6, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 4 molecules, respectively.

Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hairy Cell Leukemia - Overview
Hairy Cell Leukemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hairy Cell Leukemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hairy Cell Leukemia - Companies Involved in Therapeutics Development
AbbVie Inc
Ascentage Pharma Group International
AstraZeneca Plc
Autolus Therapeutics Plc
Bristol-Myers Squibb Co
Eureka Therapeutics Inc
F. Hoffmann-La Roche Ltd
Incyte Corp
Jecho Biopharmaceuticals Co Ltd
MacroGenics Inc
Mediolanum farmaceutici SpA
Mustang Bio Inc
Novartis AG
Sorrento Therapeutics Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Xi'An Yufan Biotechnology Co Ltd
Xynomic Pharmaceuticals Holdings Inc
Hairy Cell Leukemia - Drug Profiles
abivertinib maleate - Drug Profile
Product Description
Mechanism Of Action
History of Events
acalabrutinib maleate - Drug Profile
Product Description
Mechanism Of Action
History of Events
APG-2575 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AUTO-1NG - Drug Profile
Product Description
Mechanism Of Action
History of Events
CDMO-002 - Drug Profile
Product Description
Mechanism Of Action
cobimetinib fumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
History of Events
dezapelisib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ELB-021 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ET-019002 - Drug Profile
Product Description
Mechanism Of Action
GEM-155 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target CD19 for Leukemia or Lymphoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Target CD19 for Lymphoma and Leukemia - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target CD19 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target CD19 for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Target CD19 for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Target CD20 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target CD22 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target CD22 for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
ibrutinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
itacitinib adipate - Drug Profile
Product Description
Mechanism Of Action
History of Events
MB-106 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MGD-024 - Drug Profile
Product Description
Mechanism Of Action
moxetumomab pasudotox - Drug Profile
Product Description
Mechanism Of Action
History of Events
obinutuzumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Onureg - Drug Profile
Product Description
Mechanism Of Action
History of Events
parsaclisib - Drug Profile
Product Description
Mechanism Of Action
History of Events
vemurafenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
XP-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Hairy Cell Leukemia - Dormant Projects
Hairy Cell Leukemia - Discontinued Products
Hairy Cell Leukemia - Product Development Milestones
Featured News & Press Releases
Jul 21, 2021: Study: Ibrutinib effective treatment for difficult to treat forms of hairy cell leukemia
May 19, 2021: ESMO: BRAF inhibitor and Rituximab for the management of refractory or relapsed HCL
Dec 10, 2020: CHMP adopts a positive opinion for the medicinal product Lumoxiti for the treatment of relapsed or refractory hairy cell leukaemia
Jan 02, 2020: The European Medicines Agency accepts the regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukemia
Dec 08, 2019: Innate Pharma highlights FDA-approved Lumoxiti at ASH 2019
Nov 07, 2019: Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting
May 08, 2019: A patient’s 10-year journey to moxetumomab for hairy cell leukemia
Mar 12, 2019: Innate Pharma announces the appointment of Jennifer Butler appointed as executive vice president, general manager, US
Nov 27, 2018: AstraZeneca to present on Lumoxiti 2018 American Society of Hematology Annual Meeting
Nov 02, 2018: Novartis to present data on Dabrafenib and Trametinib combination at 2018 ASH annual meeting
Sep 17, 2018: AstraZeneca’s Lumoxiti secures FDA nod to treat hairy cell leukaemia
Jun 02, 2018: Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting
Apr 03, 2018: US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukaemia
Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumours
May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hairy Cell Leukemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hairy Cell Leukemia - Pipeline by AbbVie Inc, 2022
Hairy Cell Leukemia - Pipeline by Ascentage Pharma Group International, 2022
Hairy Cell Leukemia - Pipeline by AstraZeneca Plc, 2022
Hairy Cell Leukemia - Pipeline by Autolus Therapeutics Plc, 2022
Hairy Cell Leukemia - Pipeline by Bristol-Myers Squibb Co, 2022
Hairy Cell Leukemia - Pipeline by Eureka Therapeutics Inc, 2022
Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Hairy Cell Leukemia - Pipeline by Incyte Corp, 2022
Hairy Cell Leukemia - Pipeline by Jecho Biopharmaceuticals Co Ltd, 2022
Hairy Cell Leukemia - Pipeline by MacroGenics Inc, 2022
Hairy Cell Leukemia - Pipeline by Mediolanum farmaceutici SpA, 2022
Hairy Cell Leukemia - Pipeline by Mustang Bio Inc, 2022
Hairy Cell Leukemia - Pipeline by Novartis AG, 2022
Hairy Cell Leukemia - Pipeline by Sorrento Therapeutics Inc, 2022
Hairy Cell Leukemia - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, 2022
Hairy Cell Leukemia - Pipeline by Xi'An Yufan Biotechnology Co Ltd, 2022
Hairy Cell Leukemia - Pipeline by Xynomic Pharmaceuticals Holdings Inc, 2022
Hairy Cell Leukemia - Dormant Projects, 2022
Hairy Cell Leukemia - Discontinued Products, 2022

List of Figures
Number of Products under Development for Hairy Cell Leukemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM